Have your treatment recommendations for urothelial cancer patients changed given the ongoing COVID19 pandemic?  

Would you forego neoadjuvant chemotherapy?

Are you using growth factor support differently?

Any changes to immunotherapy?

Other considerations?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution